Kane Biotech Inc. Logo

Kane Biotech Inc.

KNBIF

(1.0)
Stock Price

0,07 USD

155.82% ROA

-94.49% ROE

3.39x PER

Market Cap.

17.692.046,29 USD

-330.66% DER

0% Yield

423.52% NPM

Kane Biotech Inc. Stock Analysis

Kane Biotech Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Kane Biotech Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (137.22%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's PBV ratio (1.32x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

4 ROA

The stock's ROA (-66.32%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 DER

The stock is burdened with a heavy load of debt (145%), making it financially unstable and potentially risky for investors.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Kane Biotech Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Kane Biotech Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Sell
4 Stoch RSI Buy

Kane Biotech Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Kane Biotech Inc. Revenue
Year Revenue Growth
2003 76.640
2004 13.414 -471.34%
2005 22.115 39.34%
2006 24.098 8.23%
2007 17.156 -40.46%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 159.945 100%
2014 41.899 -281.74%
2015 104.624 59.95%
2016 244.756 57.25%
2017 1.035.302 76.36%
2018 506.273 -104.49%
2019 1.693.524 70.11%
2020 1.341.574 -26.23%
2021 1.607.775 16.56%
2022 2.668.352 39.75%
2023 2.871.408 7.07%
2023 148.980 -1827.38%
2024 2.481.748 94%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Kane Biotech Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2003 167.575
2004 275.483 39.17%
2005 430.950 36.08%
2006 415.820 -3.64%
2007 423.697 1.86%
2008 520.304 18.57%
2009 325.813 -59.69%
2010 423.754 23.11%
2011 146.505 -189.24%
2012 176.803 17.14%
2013 48.952 -261.18%
2014 757.398 93.54%
2015 403.863 -87.54%
2016 573.423 29.57%
2017 850.578 32.58%
2018 922.526 7.8%
2019 1.541.381 40.15%
2020 1.326.127 -16.23%
2021 1.377.250 3.71%
2022 1.053.992 -30.67%
2023 1.109.632 5.01%
2023 1.286.758 13.77%
2024 1.939.680 33.66%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Kane Biotech Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 487.682 100%
2009 505.052 3.44%
2010 476.687 -5.95%
2011 1.019.463 53.24%
2012 1.201.767 15.17%
2013 1.226.086 1.98%
2014 787.915 -55.61%
2015 1.389.677 43.3%
2016 2.116.764 34.35%
2017 2.757.279 23.23%
2018 2.371.777 -16.25%
2019 2.658.727 10.79%
2020 3.425.105 22.38%
2021 4.074.748 15.94%
2022 3.723.046 -9.45%
2023 4.942.984 24.68%
2023 2.412.956 -104.85%
2024 3.913.908 38.35%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Kane Biotech Inc. EBITDA
Year EBITDA Growth
2003 -387.109
2004 -586.597 34.01%
2005 -995.754 41.09%
2006 -832.609 -19.59%
2007 -929.258 10.4%
2008 -954.766 2.67%
2009 -817.328 -16.82%
2010 -849.927 3.84%
2011 -1.165.968 27.11%
2012 -1.274.446 8.51%
2013 -1.345.538 5.28%
2014 -1.474.161 8.73%
2015 -1.682.638 12.39%
2016 -2.514.381 33.08%
2017 -2.609.685 3.65%
2018 -3.097.431 15.75%
2019 -3.426.695 9.61%
2020 -3.647.911 6.06%
2021 -4.249.860 14.16%
2022 -2.745.190 -54.81%
2023 -4.465.300 38.52%
2023 -3.234.415 -38.06%
2024 -4.194.048 22.88%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Kane Biotech Inc. Gross Profit
Year Gross Profit Growth
2003 76.640
2004 13.414 -471.34%
2005 22.115 39.34%
2006 24.098 8.23%
2007 17.156 -40.46%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 159.945 100%
2014 22.330 -616.28%
2015 59.594 62.53%
2016 120.531 50.56%
2017 912.899 86.8%
2018 115.471 -690.59%
2019 609.912 81.07%
2020 526.859 -15.76%
2021 568.441 7.32%
2022 1.413.229 59.78%
2023 1.261.060 -12.07%
2023 109.470 -1051.97%
2024 1.441.988 92.41%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Kane Biotech Inc. Net Profit
Year Net Profit Growth
2003 -405.542
2004 -602.562 32.7%
2005 -1.009.650 40.32%
2006 -955.759 -5.64%
2007 -1.089.955 12.31%
2008 -1.076.844 -1.22%
2009 -877.247 -22.75%
2010 -973.254 9.86%
2011 -1.221.149 20.3%
2012 -1.459.495 16.33%
2013 -1.447.365 -0.84%
2014 -1.614.908 10.37%
2015 -1.709.997 5.56%
2016 -2.548.748 32.91%
2017 -2.786.174 8.52%
2018 -3.260.999 14.56%
2019 -960.178 -239.62%
2020 -3.716.686 74.17%
2021 -4.604.566 19.28%
2022 -3.889.892 -18.37%
2023 -5.513.604 29.45%
2023 -4.562.345 -20.85%
2024 36.730.044 112.42%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Kane Biotech Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Kane Biotech Inc. Free Cashflow
Year Free Cashflow Growth
2003 -417.455
2004 -507.598 17.76%
2005 -1.124.015 54.84%
2006 -1.028.756 -9.26%
2007 -965.570 -6.54%
2008 -1.223.933 21.11%
2009 -884.336 -38.4%
2010 -922.379 4.12%
2011 -1.056.529 12.7%
2012 -1.248.540 15.38%
2013 -1.299.852 3.95%
2014 -1.235.947 -5.17%
2015 -1.497.985 17.49%
2016 -2.629.354 43.03%
2017 -2.273.883 -15.63%
2018 -3.000.298 24.21%
2019 -1.052.748 -185%
2020 -4.065.082 74.1%
2021 -2.642.735 -53.82%
2022 -3.131.021 15.6%
2023 -748.059 -318.55%
2023 -3.230.841 76.85%
2024 -2.202.434 -46.69%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Kane Biotech Inc. Operating Cashflow
Year Operating Cashflow Growth
2003 -404.872
2004 -503.499 19.59%
2005 -808.870 37.75%
2006 -843.129 4.06%
2007 -798.377 -5.61%
2008 -1.073.400 25.62%
2009 -764.261 -40.45%
2010 -792.058 3.51%
2011 -940.305 15.77%
2012 -1.155.293 18.61%
2013 -1.166.443 0.96%
2014 -1.049.161 -11.18%
2015 -1.388.494 24.44%
2016 -2.363.319 41.25%
2017 -2.044.247 -15.61%
2018 -2.853.997 28.37%
2019 -955.372 -198.73%
2020 -3.938.970 75.75%
2021 -2.289.190 -72.07%
2022 -3.043.472 24.78%
2023 -715.266 -325.5%
2023 -3.221.626 77.8%
2024 -2.169.158 -48.52%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Kane Biotech Inc. Capital Expenditure
Year Capital Expenditure Growth
2003 12.583
2004 4.099 -206.98%
2005 315.145 98.7%
2006 185.627 -69.77%
2007 167.193 -11.03%
2008 150.533 -11.07%
2009 120.075 -25.37%
2010 130.321 7.86%
2011 116.224 -12.13%
2012 93.247 -24.64%
2013 133.409 30.1%
2014 186.786 28.58%
2015 109.491 -70.59%
2016 266.035 58.84%
2017 229.636 -15.85%
2018 146.301 -56.96%
2019 97.376 -50.24%
2020 126.112 22.79%
2021 353.545 64.33%
2022 87.549 -303.83%
2023 32.793 -166.97%
2023 9.215 -255.87%
2024 33.276 72.31%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Kane Biotech Inc. Equity
Year Equity Growth
2003 955.274
2004 426.648 -123.9%
2005 1.017.430 58.07%
2006 1.424.773 28.59%
2007 1.140.734 -24.9%
2008 1.492.749 23.58%
2009 1.797.319 16.95%
2010 1.163.616 -54.46%
2011 2.378.083 51.07%
2012 2.348.074 -1.28%
2013 1.283.198 -82.99%
2014 1.324.919 3.15%
2015 480.246 -175.88%
2016 1.347.495 64.36%
2017 2.738.052 50.79%
2018 -984.840 378.02%
2019 836.807 217.69%
2020 1.074.736 22.14%
2021 -1.567.014 168.58%
2022 -4.137.711 62.13%
2023 -7.013.254 41%
2023 -8.409.392 16.6%
2024 -721.699 -1065.22%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Kane Biotech Inc. Assets
Year Assets Growth
2003 1.012.298
2004 526.372 -92.32%
2005 1.152.053 54.31%
2006 1.517.608 24.09%
2007 1.228.592 -23.52%
2008 1.572.311 21.86%
2009 1.865.937 15.74%
2010 1.254.364 -48.76%
2011 2.470.808 49.23%
2012 2.524.800 2.14%
2013 1.883.509 -34.05%
2014 1.989.430 5.32%
2015 1.173.109 -69.59%
2016 2.131.211 44.96%
2017 3.397.087 37.26%
2018 1.555.936 -118.33%
2019 2.755.692 43.54%
2020 5.035.619 45.28%
2021 6.134.293 17.91%
2022 5.619.835 -9.15%
2023 6.010.932 6.51%
2023 5.680.919 -5.81%
2024 4.073.838 -39.45%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Kane Biotech Inc. Liabilities
Year Liabilities Growth
2003 57.024
2004 99.724 42.82%
2005 134.623 25.92%
2006 92.835 -45.01%
2007 87.858 -5.66%
2008 79.562 -10.43%
2009 68.618 -15.95%
2010 90.748 24.39%
2011 92.725 2.13%
2012 176.726 47.53%
2013 600.311 70.56%
2014 664.511 9.66%
2015 692.863 4.09%
2016 783.716 11.59%
2017 659.035 -18.92%
2018 2.540.776 74.06%
2019 1.918.885 -32.41%
2020 3.960.883 51.55%
2021 7.701.307 48.57%
2022 9.757.546 21.07%
2023 13.024.186 25.08%
2023 14.090.311 7.57%
2024 4.795.537 -193.82%

Kane Biotech Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0.04
Price to Earning Ratio
3.39x
Price To Sales Ratio
137.44x
POCF Ratio
-3.05
PFCF Ratio
-3.04
Price to Book Ratio
-24.49
EV to Sales
148.14
EV Over EBITDA
-4.59
EV to Operating CashFlow
-3.29
EV to FreeCashFlow
-3.28
Earnings Yield
0.29
FreeCashFlow Yield
-0.33
Market Cap
0,02 Bil.
Enterprise Value
0,02 Bil.
Graham Number
0.07
Graham NetNet
-0.02

Income Statement Metrics

Net Income per Share
0.04
Income Quality
-1.24
ROE
-0.65
Return On Assets
1.43
Return On Capital Employed
-3.47
Net Income per EBT
-1.19
EBT Per Ebit
1.18
Ebit per Revenue
-3.01
Effective Tax Rate
-0.04

Margins

Sales, General, & Administrative to Revenue
25.61
Research & Developement to Revenue
13.22
Stock Based Compensation to Revenue
6.77
Gross Profit Margin
-0.08
Operating Profit Margin
-3.01
Pretax Profit Margin
-3.56
Net Profit Margin
4.24

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.04
Free CashFlow per Share
-0.04
Capex to Operating CashFlow
-0
Capex to Revenue
0.16
Capex to Depreciation
0.09
Return on Invested Capital
2.43
Return on Tangible Assets
1.56
Days Sales Outstanding
1243.21
Days Payables Outstanding
130.83
Days of Inventory on Hand
186.32
Receivables Turnover
0.29
Payables Turnover
2.79
Inventory Turnover
1.96
Capex per Share
0

Balance Sheet

Cash per Share
0,01
Book Value per Share
-0,01
Tangible Book Value per Share
-0.01
Shareholders Equity per Share
-0.01
Interest Debt per Share
0.02
Debt to Equity
-3.31
Debt to Assets
0.59
Net Debt to EBITDA
-0.33
Current Ratio
0.82
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
1229440
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.18
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
485232.5
Debt to Market Cap
0.13

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Kane Biotech Inc. Dividends
Year Dividends Growth

Kane Biotech Inc. Profile

About Kane Biotech Inc.

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

CEO
Mr. Marc Edwards
Employee
0
Address
290-100 Innovation Drive
Winnipeg, R3T 6G2

Kane Biotech Inc. Executives & BODs

Kane Biotech Inc. Executives & BODs
# Name Age
1 Mr. Marc Edwards
President, Chief Executive Officer & Director
70
2 Dr. Robert B. Huizinga CNeph(C), M.Sc., MSc(Epi), Ph.D., R.N., RN NNC
Executive Chairman & Member of Scientific Advisory Board
70
3 Ms. Lori Christofalos
Chief Quality Officer
70
4 Lorne Gorber
Investor Relations
70
5 Mr. Ray Dupuis
Chief Financial Officer
70
6 Nicole Sendey
Investor Relations Adviser
70
7 Ms. Wendy Nachtigall
Director of Marketing
70
8 Dr. Gregory S. Schultz Ph.D.
Chief Scientific Officer & Member of Scientific Advisory Board
70

Kane Biotech Inc. Competitors